EUCTR2014-005137-32-DE进行中（未招募）1 期
A Phase I-IIa, Open label, Multi-Center, Dose Escalating Study to Evaluate the Safety of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate (Oncocort) as Monotherapy in Patients with Previously Treated Progressive Multiple Myeloma - AMETHYST-trial
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Previously diagnosed symptomatic MM according to International Myeloma Working Group (IMWG) criteria
- •a.Previously treated with at least two therapy lines including at least one proteasome-inhibitor and at least one immunomodulatory drug
- •b.Relapse after or progressive disease under last therapy according to IMWG criteria.
- •2.At least 18 years old
- •3.Measurable disease (M-protein and/or free light chains) in serum and/or urine
- •4.Willing and able to comply the study protocol visits and assessments
- •5.Willing to use highly effective methods of birth control
- •6.Written informed consent prior to study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 22
排除标准
- •1.Types of Multiple Myeloma previously shown to be irresponsive to dexamethasone monotherapy during the last 6 months
- •2.Plasma cell leukemia
- •3.Subject with positive hepatitis panel (including hepatitis B surface antigen [HBsAg], and / or anti-hepatitis B core antibodies, and / or hepatitis C virus antibody [anti-HCV]), and / or a positive HIV antibody screen
- •4.Severe abnormal organ function or laboratory results at the time of the Screening Visit: WBC <3.0 g/L, ANC <1.5 G/L, PLT <50 G/L, Sodium <135 mmol/L or >150 mmol/L, potassium <3.5 mmol/L or >5.5 mmol/L, calcium <2.0 mmol/L or > 2.9mmol/L, phosphorus <0.8 mmol/L, total bilirubin >1.5x ULN, AP >2.5x ULN, gammaGT >3x ULN, ALT >3x ULN, CK >2.5x ULN, Creatinine >2x ULN, fasting glucose >250 mg/dL, albumin <3 g/dL, cholesterol >300 mg/dL
- •5.Treatment with oral or injectable (including intra-articular) corticosteroids (CS) within 4 weeks prior to Screening Visit. Inhaled and dermal corticosteroid formulations are allowed.
- •6.Subjects who have received a chemotherapeutic treatment cycle including dexamethasone within 4 weeks prior to the Screening Visit
- •7.Known sensitivity to any component of the study drug or previous hypersensitivity reaction or other clinically significant reaction to intravenous medications, biologic therapy or IV radiocontrast agents
- •8.Active infection requiring systemic treatment
- •9.Planned major surgery during the study period or had undergone major surgery within 30 days prior to the Screening visit.
- •10.Pregnancy or breastfeeding
- •11.Prior history of pulmonary embolism
- •12.Prior history of gastrointestinal hemorrhage
- •13.Prior history of a psychiatric disorder
- •14.Any clinically significant hepatic, renal, cardiac, pulmonary, gastrointestinal, metabolic or endocrine disturbances, other medical or psychiatric condition, or clinically relevant abnormal values on any investigation, in the opinion of the Investigator, that could make the subject unsuitable for the study, could compromise subject safety, limit the subject’s ability to complete the study, and/or compromise the objectives of the study, including severe neuropathies or other painful conditions that might interfere with pain evaluation
- •15.Participation in another clinical investigation less than 4 weeks prior to inclusion
- •16.The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.
- •17.The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study18.The subject is unwilling or unable to follow the procedures outlined in the protocol
- •19.The subject is mentally or legally incapacitated
- •20.Persons who are in a relationship of dependence to the Investigator or the Sponsor
研究者
相似试验
已完成
1 期
A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination with Standard Therapy in Subjects with Relapsed/Refractory Multiple MyelomaC90.0Multiple myelomaDRKS00003145MorphoSys AG91
进行中（未招募）
1 期
A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injectioEUCTR2011-002044-28-DEShire Human Genetics Therapies Inc24
进行中（未招募）
1 期
A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injectioEUCTR2011-002044-28-DKShire Human Genetics Therapies Inc24
进行中（未招募）
1 期
A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid TumorsRelapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC)MedDRA version: 20.0Level: LLTClassification code 10009963Term: Colon carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10007336Term: Carcinoma colon recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: LLTClassification code 10082179Term: Squamous cell carcinoma of head and neck metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002177-25-ESektar Therapeutics78
进行中（未招募）
1 期
A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid TumorsRelapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC)MedDRA version: 22.0Level: LLTClassification code 10082179Term: Squamous cell carcinoma of head and neck metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10009963Term: Colon carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10007336Term: Carcinoma colon recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002177-25-ITEKTAR THERAPEUTICS78